# Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Source: https://onco.cc/trials/nct06127407/  
OnCo record `nct06127407` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivosidenib in sarcomas, run by Servier Bio-Innovation LLC, now recruiting.

## Summary

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen is a phase 3 interventional study registered as NCT06127407 by Servier Bio-Innovation LLC, with 136 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ivosidenib 500mg and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06127407
- Phase: 3
- Setting: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Sponsor: Servier Bio-Innovation LLC
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT06127407: https://clinicaltrials.gov/study/NCT06127407

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Ivosidenib](https://onco.cc/drugs/ivosidenib/)

---
JSON: https://onco.cc/api/v1/entities/nct06127407.json